KCNH2 and Ventricular arrhythmia: A safety margin of at least 30-fold between the IC50 for hERG inhibition and the maximum plasma concentration achieved in clinical practice has been suggested as being adequate for predicting the safety of a drug with respect to risk for ventricular arrhythmias [10].